Investors Purchase High Volume of Heron Therapeutics Call Options (NASDAQ:HRTX)

Heron Therapeutics Inc (NASDAQ:HRTX) saw unusually large options trading on Monday. Stock traders bought 6,991 call options on the stock. This is an increase of approximately 801% compared to the average volume of 776 call options.

Heron Therapeutics stock opened at $14.71 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.53 and a quick ratio of 4.17. Heron Therapeutics has a 1-year low of $9.60 and a 1-year high of $26.81. The company has a market cap of $1.33 billion, a PE ratio of -6.48 and a beta of 1.55. The stock’s 50 day moving average price is $18.33 and its 200 day moving average price is $18.49.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported ($0.57) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.08. The company had revenue of $25.40 million for the quarter, compared to the consensus estimate of $21.23 million. Heron Therapeutics had a negative return on equity of 56.85% and a negative net margin of 138.31%. Heron Therapeutics’s quarterly revenue was down 19.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.80) earnings per share. On average, equities research analysts anticipate that Heron Therapeutics will post -2.33 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of HRTX. Sowell Financial Services LLC boosted its position in Heron Therapeutics by 2,443.5% during the first quarter. Sowell Financial Services LLC now owns 2,340 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 2,248 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Heron Therapeutics by 325.6% during the first quarter. PNC Financial Services Group Inc. now owns 2,698 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 2,064 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its position in Heron Therapeutics by 259.7% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,579 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 1,862 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Heron Therapeutics by 82.1% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,896 shares of the biotechnology company’s stock worth $116,000 after purchasing an additional 4,463 shares in the last quarter. Finally, X Square Capital LLC purchased a new stake in Heron Therapeutics during the first quarter worth $117,000.

HRTX has been the topic of several research analyst reports. Guggenheim initiated coverage on Heron Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $24.00 price target on the stock. FIX began coverage on Heron Therapeutics in a report on Monday, May 18th. They issued an “add” rating on the stock. Zacks Investment Research lowered Heron Therapeutics from a “buy” rating to a “hold” rating and set a $18.00 target price on the stock. in a report on Wednesday, May 20th. Needham & Company LLC reissued a “buy” rating and issued a $44.00 target price on shares of Heron Therapeutics in a report on Wednesday, April 15th. Finally, Northland Securities began coverage on Heron Therapeutics in a report on Monday, June 22nd. They issued a “buy” rating and a $47.00 target price on the stock. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Heron Therapeutics has an average rating of “Buy” and a consensus price target of $36.10.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

See Also: FinTech

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.